STK11m may co-occur with mutations in KRAS (KRASm), a common oncogenic driver in NSCLC [33, 34], and the presence of dual STK11 and KRAS mutations has been associated with a trend towards poorer survival outcomes in NSCLC in response to chemotherapy and IO [20, 21, 23]. Here, KRAS is linked to non-small cell lung carcinoma.